×
S&P 500   3,892.19 (+1.23%)
DOW   31,279.74 (+0.78%)
QQQ   294.00 (+1.80%)
AAPL   145.88 (+2.07%)
MSFT   267.63 (+0.53%)
META   171.70 (+1.14%)
GOOGL   2,355.99 (+2.82%)
AMZN   116.22 (+1.65%)
TSLA   732.27 (+5.33%)
NVDA   157.93 (+4.38%)
NIO   22.45 (+7.78%)
BABA   123.32 (+3.53%)
AMD   79.12 (+5.00%)
MU   58.31 (+1.64%)
CGC   2.70 (+1.89%)
T   21.13 (+0.19%)
GE   62.42 (+1.38%)
F   11.60 (+4.88%)
DIS   96.98 (+0.94%)
AMC   14.11 (+12.25%)
PFE   53.11 (+0.68%)
PYPL   74.54 (+1.77%)
NFLX   189.11 (+2.74%)
S&P 500   3,892.19 (+1.23%)
DOW   31,279.74 (+0.78%)
QQQ   294.00 (+1.80%)
AAPL   145.88 (+2.07%)
MSFT   267.63 (+0.53%)
META   171.70 (+1.14%)
GOOGL   2,355.99 (+2.82%)
AMZN   116.22 (+1.65%)
TSLA   732.27 (+5.33%)
NVDA   157.93 (+4.38%)
NIO   22.45 (+7.78%)
BABA   123.32 (+3.53%)
AMD   79.12 (+5.00%)
MU   58.31 (+1.64%)
CGC   2.70 (+1.89%)
T   21.13 (+0.19%)
GE   62.42 (+1.38%)
F   11.60 (+4.88%)
DIS   96.98 (+0.94%)
AMC   14.11 (+12.25%)
PFE   53.11 (+0.68%)
PYPL   74.54 (+1.77%)
NFLX   189.11 (+2.74%)
S&P 500   3,892.19 (+1.23%)
DOW   31,279.74 (+0.78%)
QQQ   294.00 (+1.80%)
AAPL   145.88 (+2.07%)
MSFT   267.63 (+0.53%)
META   171.70 (+1.14%)
GOOGL   2,355.99 (+2.82%)
AMZN   116.22 (+1.65%)
TSLA   732.27 (+5.33%)
NVDA   157.93 (+4.38%)
NIO   22.45 (+7.78%)
BABA   123.32 (+3.53%)
AMD   79.12 (+5.00%)
MU   58.31 (+1.64%)
CGC   2.70 (+1.89%)
T   21.13 (+0.19%)
GE   62.42 (+1.38%)
F   11.60 (+4.88%)
DIS   96.98 (+0.94%)
AMC   14.11 (+12.25%)
PFE   53.11 (+0.68%)
PYPL   74.54 (+1.77%)
NFLX   189.11 (+2.74%)
S&P 500   3,892.19 (+1.23%)
DOW   31,279.74 (+0.78%)
QQQ   294.00 (+1.80%)
AAPL   145.88 (+2.07%)
MSFT   267.63 (+0.53%)
META   171.70 (+1.14%)
GOOGL   2,355.99 (+2.82%)
AMZN   116.22 (+1.65%)
TSLA   732.27 (+5.33%)
NVDA   157.93 (+4.38%)
NIO   22.45 (+7.78%)
BABA   123.32 (+3.53%)
AMD   79.12 (+5.00%)
MU   58.31 (+1.64%)
CGC   2.70 (+1.89%)
T   21.13 (+0.19%)
GE   62.42 (+1.38%)
F   11.60 (+4.88%)
DIS   96.98 (+0.94%)
AMC   14.11 (+12.25%)
PFE   53.11 (+0.68%)
PYPL   74.54 (+1.77%)
NFLX   189.11 (+2.74%)
NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$604.68
+9.78 (+1.64%)
(As of 07/7/2022 12:57 PM ET)
Add
Compare
Today's Range
$595.97
$604.84
50-Day Range
$548.35
$692.80
52-Week Range
$538.01
$747.42
Volume
9,148 shs
Average Volume
687,434 shs
Market Capitalization
$65.63 billion
P/E Ratio
8.56
Dividend Yield
N/A
Price Target
$707.43

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.58 Rating Score
Upside/​Downside
17.1% Upside
$707.43 Price Target
Short Interest
Healthy
2.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.17mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$7.63 M Sold Last Quarter
Proj. Earnings Growth
5.59%
From $40.63 to $42.90 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.36 out of 5 stars

Medical Sector

133rd out of 1,433 stocks

Pharmaceutical Preparations Industry

48th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Regeneron Pharmaceuticals logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Company Calendar

Last Earnings
5/04/2022
Today
7/07/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$707.43
High Stock Price Forecast
$844.00
Low Stock Price Forecast
$536.00
Forecasted Upside/Downside
+17.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57894736842105
Research Coverage
19 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
55.33%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$81.93 per share
Book Value
$172.92 per share

Miscellaneous

Free Float
95,688,000
Market Cap
$65.63 billion
Optionable
Optionable
Beta
0.31

Social Links















Regeneron Pharmaceuticals Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2022?

19 brokers have issued 12 month price objectives for Regeneron Pharmaceuticals' stock. Their REGN stock forecasts range from $536.00 to $844.00. On average, they predict Regeneron Pharmaceuticals' share price to reach $707.43 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Regeneron Pharmaceuticals' stock performed in 2022?

Regeneron Pharmaceuticals' stock was trading at $631.52 at the beginning of 2022. Since then, REGN stock has decreased by 4.5% and is now trading at $603.00.
View the best growth stocks for 2022 here
.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its earnings results on Wednesday, May, 4th. The biopharmaceutical company reported $11.49 earnings per share for the quarter, beating analysts' consensus estimates of $9.37 by $2.12. The biopharmaceutical company earned $2.97 billion during the quarter, compared to analysts' expectations of $2.69 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 50.10% and a net margin of 48.06%. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $10.09 earnings per share.
View Regeneron Pharmaceuticals' earnings history
.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Parsec Financial Management Inc. (0.01%), Fulton Bank N.A. (0.00%), Pensionfund Sabic (0.00%) and Adirondack Trust Co. (0.00%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Pensionfund Sabic. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last two years include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including Parsec Financial Management Inc., Adirondack Trust Co., and Fulton Bank N.A..
View insider buying and selling activity for Regeneron Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $603.00.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $65.45 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $70.60 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for Regeneron Pharmaceuticals is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.